![](https://investorshub.advfn.com/uicon/430424.png?cb=1554906782)
Wednesday, June 20, 2018 10:52:28 PM
1. Shipping records of dose initiation (timing) regarding placebos that evented who chose to crossover. Maybe when new doses went unused for 36 months. Whether the UCLA slide from December 15, 2016 really meant all placebo had PFS evented. Why LL chose to speak then and who her targeted audience was.
2. Reason for the screening halt. Complete reason it was lifted. (Aka: full backstory)
3. Probably more frequently updated on OS eventing then yearly, because at one time back in 2017, Les gave me the impression he was updated far more frequently.
4. Blinded immune responses of patients.
5. Actual current status of LTFU and where they fall on the curve.
6. Enough or not enough information to still believe and state on June 3, 2018 that DCVax-L could become the frontline therapy for GBM.
7. What is truly the guiding principle for moving towards unblinding.
8. What is the current price NWBO thinks DCVax-L should be worth.
9. What capacity Cognate currently has to produce enough DCVax-L to meet expected demand in the United states.
10. Expected date for Advent to be prepared for commercial production.
11. Why she provided a loan that comes due in August.
12. The likelihood of meeting NICE timeline.
13. The likelihood and possible expected date for filing for marketing authorization in various countries/unions.
14. Whether or not efficacy IAs have been performed, and if they were performed, what their basic results/recommendations were.
15. Why they voluntarily halted enrolling in Germany around the same time as the screening halt.
16. Current rate of eventing, and how many surviving.
17. Why she believes the tail (of the KM survival curve) could get thicker when her own 69 investigators state there is no meaningful difference in survival based upon the year one was enrolled -- in an eleven year old trial.
18. Whether and to what degree manufacturing optimizations were made during the trial.
19. Why there is a randomization imbalance.
20. Lot's more.
Respect Risk. Conduct Your Own Due Diligence. Manage your assets wisely. Diversify.
Recent NWBO News
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 09/03/2024 08:01:40 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 08/13/2024 08:01:24 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/09/2024 09:06:07 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 08/08/2024 08:30:09 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 08/02/2024 02:42:28 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 07/30/2024 11:49:38 PM
- Biophma Announces Exclusive In License for Dendritic Cell Technology, Sending Shares Higher • AllPennyStocks.com • 06/17/2024 04:40:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 06/04/2024 09:11:16 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 06/03/2024 09:22:55 PM
- Form PRE 14A - Other preliminary proxy statements • Edgar (US Regulatory) • 05/22/2024 08:13:36 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 05/10/2024 09:04:57 PM
- Form NT 10-K - Notification of inability to timely file Form 10-K 405, 10-K, 10-KSB 405, 10-KSB, 10-KT, or 10-KT405 • Edgar (US Regulatory) • 03/01/2024 10:04:38 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 12/02/2023 01:31:35 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/16/2023 10:11:54 PM
- Epazz, Inc. (OTC Pink: EPAZ) ZenaDrone Demonstration to Defense Departments of UAE and Saudi Arabia • InvestorsHub NewsWire • 11/15/2023 12:19:31 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/09/2023 09:30:39 PM
- Epazz, Inc. (OTC Pink: EPAZ) US Navy Collaboration ZenaDrone 1000 • InvestorsHub NewsWire • 11/09/2023 01:00:34 PM
- Epazz, Inc. (OTC Pink: EPAZ) US Navy Collaboration ZenaDrone 1000 Extreme Weather Demo • InvestorsHub NewsWire • 11/07/2023 12:29:43 PM
Simple Stock Loans Announces Unique Solutions For Investors Looking for Alternative Liquidity Amidst Recent Small Cap Rally Sep 6, 2024 9:30 AM
Reliant Coffee Debuts at #271 on the Inc. 5000 List of Fastest Growing Companies - Coffee Service Industry Disruptor Brews Up Exponential Growth Sep 5, 2024 11:51 AM
VAYK Confirms Receiving Revenue from First Airbnb Property with 1.4 Million Annual Revenue Goal • VAYK • Sep 4, 2024 9:34 AM
Mawson Finland Limited Expands Known Mineralized Zones at Rajapalot: New Lens Intercepts 21.75 m at 5.25 g/t Gold & 515 ppm Cobalt • MFL • Sep 4, 2024 9:02 AM
Integrated Ventures Acquires 51% Stake In GetTrim.Com (TM), Telemedicine Platform With Focus On Expansion Into Booming GLP-1 Powered Weight Loss Market • INTV • Sep 4, 2024 8:45 AM
Avant Technologies Announces Strategic Review Process Intended to Maximize Shareholder Value • AVAI • Sep 4, 2024 8:00 AM